The White House says the most-favored-nation drug-pricing agreements it announced this week will save state and federal Medicaid budgets a combined $64.3 billion over the next ten years, a figure produced by the administration’s own Council of Economic Advisers rather than an independent scorekeeper. The number accompanies this month’s announcement that 26 drugmakers have agreed to extend their lowest overseas prices to Medicaid programs nationwide. For a program that pays for prescriptions, nursing-home care, and other services for tens of millions of low-income Americans, a ten-year projection is worth reading for what it actually promises: a modeled outcome, not a check that has been cut.
What the $64.3 Billion Splits Into
The Council of Economic Advisers’ estimate divides the projected savings between the two levels of government that jointly fund Medicaid. Roughly $36.6 billion of the ten-year total is projected to accrue to the federal government, with the remaining $27.6 billion projected for state governments, reflecting the standard formula under which Washington and the states split most Medicaid costs.
Both figures come directly from the White House fact sheet announcing the deal, which describes the number as an estimate rather than an audited or realized result. The same document separately projects that the administration’s broader most-favored-nation strategy, covering direct consumer sales and other programs alongside Medicaid, could save $600 billion over the same decade, a second, larger estimate built on the same modeling exercise.
Free download: IRMAA, the Medicare Savings Programs and Extra Help explained side by side, with the official form and contact for each. Get the free Medicare premium route finder.
An Executive Branch Estimate, Not an Independent Score
The Council of Economic Advisers sits inside the White House and answers to the president, distinguishing its estimate from the kind of independent analysis the Congressional Budget Office produces for legislation moving through Congress. That distinction does not make the $64.3 billion figure wrong, but it does mean the number reflects the assumptions of the office that designed the program being measured, rather than a third party’s independent projection. CMS’s own announcement of the program repeats the same $64.3 billion figure, describing it as the estimated saving from a model that launched in January 2026 and runs for five years, meaning the real test of the number will play out over a period longer than the model’s own funding window.
Why the State Half of the Estimate Doesn’t Reach a Beneficiary Directly
Medicaid financing gives states wide discretion over how they spend money freed up by lower drug costs, and the fact sheet frames that freed capital as available for other services to vulnerable residents rather than a rebate that returns to an individual enrollee’s pocket. That framing matches how Medicaid rebate savings have typically worked: when a state’s drug costs fall, the difference tends to show up in the next budget cycle as room to spend elsewhere, not as a payment mailed to an enrollee. Whether a given state actually redirects its share toward the older and disabled Medicaid populations most likely to use expensive drugs, as opposed to closing a different budget gap, is a decision each state legislature makes on its own timeline, separate from the ten-year modeling exercise that produced the $64.3 billion figure.
What Would Actually Have to Happen for the Number to Hold
Turning a projection into a realized $64.3 billion depends on steps that have not all happened yet. As of the September 18 announcement, only 40 states and Puerto Rico had signed the agreements needed to start collecting most-favored-nation rebates, with the rest facing a September 30 deadline to join. The rebates also assume manufacturers continue offering their current lowest overseas price rather than renegotiating it upward in another country, and that Medicaid drug utilization over the next decade roughly tracks the assumptions built into the estimate. The Medicaid rebates also rest on voluntary agreements the administration reached directly with each manufacturer, a different legal foundation than the mandatory Medicare drug-price negotiations Congress wrote into the Inflation Reduction Act, meaning a future administration or a shift in a manufacturer’s own pricing strategy could alter the deal’s terms in ways a statute would not allow. None of that is unusual for a ten-year government projection, but it is why the figure functions best as a marker of the deal’s intended scale rather than money a state budget office can spend today.
Reading a projected savings figure at the pharmacy counter
A projected decade of Medicaid savings does not change what a Medicare enrollee’s own drug plan charges this year, and the programs that actually cap or lower an individual’s costs today run on their own separate deadlines and appeal forms that a headline rarely spells out.
The Medicare Cost & Coverage Protection Kit is a 10-page kit with 51 state Medicare cost-help packs, the new Part D out-of-pocket cap explained, and the prior-authorization appeal steps for a denied prescription.
Look up the current Part D rules with The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by an editor.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
